期刊文献+

莫诺苷对晚期糖基化终末产物加重链脲佐菌素诱导糖尿病肾病保护作用及其机制 被引量:20

Protection of morroniside on STZ-induded diabetic nephropathy aggravated by AGEs in mice and its mechanism
原文传递
导出
摘要 目的探讨山茱萸Cornus officinalis中效应成分莫诺苷对晚期糖基化终末产物(AGEs)加重链脲佐菌素(STZ)诱导糖尿病肾病(DN)小鼠的保护机制。方法将STZ诱导成功的DN小鼠饲喂高AGEs饲料,并分别ig给予氨基胍(0.1 g/kg)、二甲双胍(0.2 g/kg)、卡托普利(0.02 g/kg)、莫诺苷低剂量(0.02 g/kg)和莫诺苷高剂量(0.10 g/kg)12周。检测空腹血糖、胰岛素、血清肌酐和尿素氮、血清和肾脏AGEs、24 h尿蛋白等指标,RT-PCR法检测肾组织中晚期糖基化终末产物受体(RAGE)m RNA表达,Westorn blotting法检测肾组织中RAGE蛋白表达,观察各组小鼠胰腺和肾脏的病理改变。结果莫诺苷可显著降低DN小鼠血糖,改善"三多一少"症状,增加胰岛素分泌,降低24 h尿蛋白、血清尿素氮和肌酐、血清和肾脏AGEs水平,缓解胰腺及肾脏病变,下调肾皮质RAGE m RNA和蛋白的表达。结论莫诺苷具有保护DN小鼠的作用,且高剂量作用较优,其相关机制可能与降低血清、肾脏AGEs水平,下调肾皮质RAGE m RNA和蛋白的表达有关。 Objective To observe the protective mechanism ofmorroniside (an active component in Comus officinalis) on the diabetic nephropathy (DN) mice induced by streptozocin (STZ) and aggravated by advanced glycation end products (AGEs). Methods The DN mice were fed with high-AGEs fodders, and ig administered with aminoguanidine (0.1 g/kg), metformin (0.2 g/kg), captopril (0.02 g/kg), low-dose morroniside (0.02 g/kg), and high-dose morroniside (0.10 g/kg) for 12 weeks. After that, the fasting glucose, insulin, serum creatinine, urea nitrogen, serum and renal AGEs, 24'h urine protein, etc were measured, the RT-PCR method was used to detect the levels of receptor for advanced glycation end products (RAGE) mRNA, the Western blotting technique was used to test the protein expression levels, and the pathologic changes of mice pancreas and kidney were observed. Results Morroniside could significantly decrease the fasting blood glucose levels, alleviate the symptoms of polydipsia, polyphagia, polyuria, and weight loss, increase the insulin production, and reduce the levels of 24 h urine protein, serum urea nitrogen, creatinine, sentrn and renal AGEs. Furthermore, morroniside could also anesis the lesions of pancreas and kidney and reduce the levels of RAGE mRNA and protein expression in renal cortex. Conclusion Morroniside has the protactive effects on DN mice and high-dose morroniside was much better. The mechanism may be related to the reduced levels of AGEs and RAGE mRNA and protein expression.
出处 《中草药》 CAS CSCD 北大核心 2014年第21期3109-3116,共8页 Chinese Traditional and Herbal Drugs
基金 国家自然科学基金资助项目(81073111) 江苏高校优势学科建设工程资助项目(Nzyzyxjg-1006)
关键词 莫诺苷 山茱萸 糖尿病肾病 晚期糖基化终末产物 晚期糖基化终末产物受体 morroniside Cornus officinalis Sieb. & Zucc. diabetic nephropathy advanced glycation end products receptor foradvanced glycation end products
  • 相关文献

参考文献18

  • 1Valmadrid C T, Klein R, Moss S E, et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with olderonset diabetes mellitus[J]. Arch Int Med, 2000, 160(8): 1093-1100.
  • 2Tsilibary E C. Microvascular basement membranes in diabetes mellitus[J]. J Pathol, 2003, 200(4): 537-546.
  • 3Garabed E M D. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation classification, and stratification[J]. Am J Kidney Dis, 2002, 39(2): S1-S246.
  • 4Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks[J]. Arch Biochem Biophys, 2003, 419(1): 89-96.
  • 5Raj D S C, Cheoudhury D, Welbourne T C, et al. Advanced glycation end products: A nephrologist's perspective[J]. Am J Kidney Dis, 2000, 35(3): 365-380.
  • 6Schwenger V, Zeler M, Henle T, et al. Advanced glycation end products (AGEs) as uremic toxins[J]. Food Nahrung, 2001, 45: 72-76.
  • 7陶玉菡,许惠琴,李莉,农伟虎,李伟.生地、山茱萸抑制和清除糖基化产物的效应成分研究[J].中药药理与临床,2013,29(4):30-33. 被引量:21
  • 8Yokozawa T, Yamabe N, Kim H Y, et al. Protective effects of morroniside isolated from Corni Fructus against renal dammage in streptozotocin-induced diabetic rats[J]. Biol Pharm Bull, 2008, 31(7): 1422-1428.
  • 9Sakai H, Abe K, Kobayashi Y, et al. Joint committee of ministry of healty and elfare of Japan and Japanese society of nephropathy. Clinical guidelines of IgA nephropathy[J]. Jpn J Nephrol, 1995, 37: 417-421.
  • 10Fukami K, Yamagishi S, Ueda S, et al. Role of AGEs in diabetic nephropathy[J]. Curr Pharm Des, 2008, 14(10): 946-952.

二级参考文献53

  • 1肖和兰,徐喆,蔡国平.糖基化终产物(AGEs)的病理意义及其抑制性药物开发原理的研究进展[J].免疫学杂志,2003,19(S1):104-109. 被引量:6
  • 2王朴.生地黄的现代药理研究与临床应用[J].中国中医药现代远程教育,2008(8):986-986. 被引量:216
  • 3付四海,黄久仪.糖基化终末产物与血管疾病[J].国外医学(生理病理科学与临床分册),2004,24(4):360-362. 被引量:11
  • 4王新嘉,何国芬,张志利,刘桂卿,张辉,王树党.橙皮苷对STZ糖尿病大鼠肾脏功能和形态的影响[J].中华内分泌代谢杂志,1996,12(1):34-36. 被引量:19
  • 5Margaret H, Anthony C,Richard B. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide[ J].Am. J. Clin Invest,1992, (90) : ll10.
  • 6Porta M, Selba ME, Molinatti P, et al. Endothelial cell function in diabeticmicroangiopathy [ J ]. Diabetalogia, 1992,(5):161.
  • 7Nudel U, Zakut R, Shard M, et al. The nucleotide .sequence of the rat cytoplasmic β-actin gene. Nucleic acids research, 1983 ; 11 (6) 1759-1771.
  • 8Bucala R, Vlassara H. Advanced glycosylation endprcxlucts in diabetic renal disease: clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition. Blood Purif, 1995, 13:160-166.
  • 9Brownlee M, Vlassara H, Kooney A, et al. Aminoguaridine prevents diabetes-induced arterial wall protein cross-linking. Science, 1986; 232:1629-1632.
  • 10Kumaril, Umar S, Bannsal V, et al. Inhibition of diabetesassociated complications by nucleophilic compounds, Diabetes, 1991 ;40:1079-1084.

共引文献332

同被引文献205

引证文献20

二级引证文献151

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部